Printer Friendly

Novartis announces Chinese approval of Cosentyx for psoriasis patients.

Novartis announced that the China Health Authority NMPA approved Cosentyx, the first-in-class interleukin-17A inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. "Reimagining the management of psoriatic disease to provide patients with the ability to live their life free from the burden of psoriasis is a key focus for us," said Paul Hudson, CEO Novartis Pharmaceuticals. "With Cosentyx, we are offering a new treatment to doctors and psoriasis patients in China which can act within 3 weeks, has demonstrated sustained safety in more than 200,000 patients worldwide and can deliver what doctors and patients are looking for."

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Apr 2, 2019
Previous Article:BARDA decides not to advance Pfenex anthrax programs.
Next Article:Exxon Mobil invests in Singapore integrated complex.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters